Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
69 hedge funds and large institutions have $144M invested in Pardes Biosciences, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 9 closing their positions.
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
21% more funds holding
Funds holding: 57 → 69 (+12)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
49% less capital invested
Capital invested by funds: $282M → $144M (-$139M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VS
VK Services
Menlo Park,
California
|
+$37.6M |
| 2 |
Goldman Sachs
New York
|
+$13.2M |
| 3 |
BlackRock
New York
|
+$7.7M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$3.28M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$7.54M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$3.29M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.24M |
| 4 |
ACM
Altium Capital Management
New York
|
-$1.83M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.41M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OCM
76
Ovata Capital Management
Hong Kong
| – | -$4K | -500 | Closed |
|
|
CS
77
Credit Suisse
Zurich,
Switzerland
| – | +$85 | +14 | New |
|
78
Fidelity Investments
Boston,
Massachusetts
| – | +$843 | +138 | New |
|
PRDS Hedge Fund Activity: Q2 2022 in Review
69 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q2 2022, worth a combined $144M — down 49% from $282M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PRDS positions and 9 closed out — a net gain of 12 holders — while 16 added to existing stakes and 20 trimmed.
The largest buyer was VK Services, opening a new position worth an estimated $37.6M. The largest seller was Frazier Life Sciences Management, cutting an estimated $7.54M.
- 69 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q2 2022, up from 57 in Q1 2022.
- Funds reported $144M of Pardes Biosciences, Inc. Common Stock stock for Q2 2022, down 49% quarter-over-quarter.
- 21 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q2 2022 and 9 closed out, a net change of +12 holders.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q2 2022 was VK Services, an estimated $37.6M added.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q2 2022 was Frazier Life Sciences Management, an estimated $7.54M sold.
Based on aggregated 13F filings for Q2 2022.